Cabaletta Bio
CABA
128 hedge funds and large institutions have $1.11B invested in Cabaletta Bio in 2023 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 41 increasing their positions, 31 reducing their positions, and 10 closing their positions.
320% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 10
78% more capital invested
Capital invested by funds: $623M → $1.11B (+$488M)
32% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 31
32% more funds holding
Funds holding: 97 → 128 (+31)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
11.44% more ownership
Funds ownership: 102.75% → 114.18% (+11%)
27% less call options, than puts
Call options by funds: $6.37M | Put options by funds: $8.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$33.1M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$30.8M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$21M |
| 4 |
State Street
Boston,
Massachusetts
|
+$17.8M |
| 5 |
PA
Perceptive Advisors
New York
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$43.8M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$26.6M |
| 3 |
FAM
Fred Alger Management
New York
|
-$15.7M |
| 4 |
CC
Commodore Capital
New York
|
-$10.5M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$6.73M |
CABA Hedge Fund Activity: Q4 2023 in Review
128 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q4 2023, worth a combined $1.11B — up 78% from $623M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new CABA positions and 10 closed out — a net gain of 32 holders — while 41 added to existing stakes and 31 trimmed.
The largest buyer was BlackRock, adding an estimated $33.1M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $43.8M sold.
- 128 institutional investors held Cabaletta Bio (CABA) as of Q4 2023, up from 97 in Q3 2023.
- Funds reported $1.11B of Cabaletta Bio stock for Q4 2023, up 78% quarter-over-quarter.
- 42 funds opened new Cabaletta Bio positions in Q4 2023 and 10 closed out, a net change of +32 holders.
- The largest Cabaletta Bio buyer in Q4 2023 was BlackRock, an estimated $33.1M added.
- The largest Cabaletta Bio seller in Q4 2023 was Cormorant Asset Management, an estimated $43.8M sold.
Based on aggregated 13F filings for Q4 2023.